ReviewJournal of enzyme inhibition and medicinal chemistry2019
Carbazole scaffolds in cancer therapy: a review from 2012 to 2018.
Review in Journal of enzyme inhibition and medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Killing Glioblastoma Cells with Glycosylated Indolocarbazole-Based Derivative LCS1269: A Potential Crosstalk Between Micronuclei Formation and the Concurrent Induction of Apoptosis, Necroptosis, and Pyroptosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Synthesis, biological evaluation, molecular docking, molecular dynamics simulation, and ADME studies of novel carbazole-aniline hybrids as cytotoxic agents.BMC chemistry · 2026Article
- Aggregation Tendency, Cellular Uptake, and Viability Effects of Structurally Distinct Carbazole-Phthalocyanine Gold Nanoconjugates.ACS organic & inorganic Au · 2026Article
- Antimicrobial, Structural, Optical, and Redox Profiling of 7ACS omega · 2025Article
- Anticancer potential of fused heterocycles: structural insights and mechanistic advances.Asian biomedicine : research, reviews and news · 2025Article
- Novel Carbazole-Thiazole Conjugates: Synthesis and Biophysical Characterization.International journal of molecular sciences · 2025Article
- Targeting Topoisomerase I and DNA with LCS1269 Drives Glioblastoma Cell Death Despite ATM/Chk1/BRCA1/RAD51 Signaling Pathway Activation.International journal of molecular sciences · 2025Article
- Anti-Breast Cancer Properties and In Vivo Safety Profile of a Bis-Carbazole Derivative.Pharmaceutics · 2025Article
- Palladium-catalyzed regioselective C1-selective nitration of carbazoles.Beilstein journal of organic chemistry · 2025Article
- Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Synthesis of Carbazole-Thiazole Dyes via One-Pot Tricomponent Reaction: Exploring Photophysical Properties, Tyrosinase Inhibition, and Molecular Docking.Sensors (Basel, Switzerland) · 2024Article
- Integrated synthesis of 3,4-carbazoquinone alkaloidsRSC advances · 2024Article
- Investigating the potential of monocyclic BJournal of molecular modeling · 2024Article
- Programming Positive Mechanofluorescence in Liquid Crystalline Elastomers.ACS applied polymer materials · 2023Article
- Design, synthesis, molecular docking and biological evaluation of new carbazole derivatives as anticancer, and antioxidant agents.BMC chemistry · 2023Article
- 5,8-Dimethyl-9Pharmaceuticals (Basel, Switzerland) · 2023Article
- Structural diversity-guided optimization of carbazole derivatives as potential cytotoxic agents.Frontiers in chemistry · 2023Article
- Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.Cancer research communications · 2022Article
- Lewis Acid-Catalyzed 2,3-Dihydrofuran Acetal Ring-Opening Benzannulations toward Functionalized 1-Hydroxycarbazoles.Molecules (Basel, Switzerland) · 2022Article
- Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic-carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.